Astellas Signs US$1.5 B Deal with Evopoint Biosciences for Novel CLDN18.2 ADC
By Swati Sharan
Pharma Deals Review: Vol 2025 Issue 6 (Table of Contents)
Published: 23 Jun-2025
DOI: 10.3833/pdr.v2025.i6.2954 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a strategic move to strengthen its oncology pipeline, Astellas Pharma has entered into an exclusive ex-China license agreement with Evopoint Biosciences for the development and commercialisation of XNW27011, a clinical-stage antibody-drug conjugate (ADC) targeting CLDN18...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS